Castle Biosciences to Present at Upcoming Investor Conferences

Rhea-AI Summary

Castle Biosciences, Inc. (CSTL) to Present Company Overview at Investor Conferences in November 2023

Positive

• Opportunity to showcase company's innovative tests and patient care guidance
• Increased visibility and potential for investor interest

Negative

• None.

FRIENDSWOOD, Texas--(BUSINESS WIRE)-- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that the Company’s executive management is scheduled to present a company overview at the following investor conferences later this month:

• Stephens Annual Investment Conference on Nov. 15, 2023, at 11:00 a.m. Eastern Time.
• Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on Nov. 16, 2023, at 9:00 a.m. Eastern time.
• Piper Sandler 35th Annual Healthcare Conference on Nov. 28, 2023, at 12:30 p.m. Eastern time.

Live audio webcasts of the Company’s presentations will be available by visiting Castle Biosciences’ website at https://ir.castlebiosciences.com/events-presentations/default.aspx. Replays of the webcasts will be available following the conclusion of the broadcasts.

About Castle Biosciences

Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.

Castle’s current portfolio consists of tests for skin cancers, uveal melanoma, Barrett’s esophagus and mental health conditions. Additionally, the Company has active research and development programs for tests in other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis, psoriasis and related conditions. To learn more, please visit www.CastleBiosciences.com and connect with us on LinkedIn, Facebook, X and Instagram.

DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, MyPath Melanoma, DecisionDx-UM, DecisionDx-PRAME, DecisionDx-UMSeq, TissueCypher and IDgenetix are trademarks of Castle Biosciences, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231108949553/en/

Investor Contact:

Camilla Zuckero

czuckero@castlebiosciences.com

Media Contact:

Allison Marshall

amarshall@castlebiosciences.com

Source: Castle Biosciences Inc.

FAQ

What is the latest announcement from Castle Biosciences, Inc. (CSTL)?

The company's executive management will be presenting a company overview at investor conferences in November 2023.

When and where will Castle Biosciences, Inc. (CSTL) be presenting at the investor conferences?

The company will present at the Stephens Annual Investment Conference on Nov. 15, Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on Nov. 16, and Piper Sandler 35th Annual Healthcare Conference on Nov. 28, all in Eastern time.

Where can I access the live webcasts of Castle Biosciences, Inc. (CSTL) presentations?

The live audio webcasts will be available on the company's website at https://ir.castlebiosciences.com/events-presentations/default.aspx.

Will there be replays of the webcasts available?

Yes, replays of the webcasts will be available after the broadcasts.